CMS Eyes Backward Step on Breakthrough Device Payment Flexibilities
CMS is proposing to roll back some payment flexibilities for breakthrough devices, potentially making it harder for innovative technologies to gain early market traction. The move could reshape how device makers think about reimbursement as much as regulation.
If FDA clearance is the door to the market, Medicare payment is the reason many devices survive there. That is why CMS’s proposal to roll back breakthrough device payment flexibilities has landed as such a consequential policy signal.
The proposed change could make commercialization harder for companies whose products are technically innovative but not yet supported by strong reimbursement pathways. For smaller firms in particular, the loss of flexible coverage rules can be more damaging than a slower regulatory review, because it affects real-world adoption and revenue.
This issue is especially important in digital health and AI-enabled devices, where evidence, clinical workflow integration, and payment policy often evolve at different speeds. A company may secure FDA clearance and still fail commercially if hospitals and payers lack a clear reason to pay for the technology.
The CMS proposal underscores a recurring theme in healthcare innovation: regulatory success is not the same as market success. As reimbursement becomes stricter, device makers will need to prove not just that their technology works, but that it saves money, improves outcomes, or solves a problem payers are willing to recognize.